A Phase 4 interventional study of Gushen Antai Pill and Placebo pill in Infertility, Female, sponsored by Shandong University of Traditional Chinese Medicine. Recruiting at 1 site in China. Open to female participants aged 21 Years to 42 Years. Per ClinicalTrials.gov, last updated 2026-03-10.
Sponsored by Shandong University of Traditional Chinese Medicine · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Infertility, Female with a site in China — 17 open to participants now, 20 under way, 1 of them phase 3. Infertility, Female · China.
Among the 58 studies in Infertility, Female with a site in China, this one is the 7th largest by planned enrollment of the 51 interventional ones that give a count, is one of 6 that started in 2021, is one of 4 in phase 4, reaches primary completion later than 8 of the 19 other live ones, and was the 29th registered.
553 studies on the registry are indexed under Infertility, Female; 133 are open to participants now.
Browse Infertility, Female studies →17 of the 58 studies in Infertility, Female with a site in China are open now. Recruiting first, the newest first:
Peking University Third Hospital · Sites in China
Ages 18–40 · Women only
Shandong University of Traditional Chinese Medicine · Sites in China
Ages 21–44 · Women only
Tang-Du Hospital · Sites in China
Ages 20–40 · Women only
Suzhou Centergene Pharmaceuticals Co.,Ltd. · Sites in China
Ages 20–40 · Women only · Healthy volunteers
Peking University Third Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 88 Infertility, Female studies recruiting now, 11 (13%) set no upper age limit and 77 (88%) stop at 75 or younger; 9 take children under 18; 29 take healthy volunteers.
This study: 21 Years to 42 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 1 · Phase 3 6 · Phase 4 4
First in 2014; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 800 is above the median of 100 across 378 interventional studies indexed under Infertility, Female.
Median enrollment 178 across the 51 interventional studies, 2,569 across the 7 observational. Of the 19 that completed or were terminated, 3 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 58 have an industry lead sponsor. The 10 most frequent:
Shandong University of Traditional Chinese Medicine is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Shandong University of Traditional Chinese Medicine has 3 studies filed under Infertility, Female — fewer than ten, so there is no comparison to draw.
4 of the studies in Infertility, Female with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06644794Phase 3Shandong University of Traditional Chinese MedicineProgesterone-modified Natural Cycle for FET | 2027-09-10 |
| NCT06775093Peking University Third HospitalEffects of GLP-1RAs on Reproductive Outcomes in PCOS and Obesity | 2026-12-31 |
| NCT06020924Wenwen WangThe Effects of Uterine Fibroids on Pregnancy in Women | 2026-12-31 |
| NCT07409792Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical UniversityMultifaceted Benefits of Auricular Point Sticking for IVF Patients: Psychological Well-being, Sleep, and Treatment Outcomes | 2027-01-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 58 studies in Infertility, Female with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate whether oral Gushen Antai pills supplementation for luteal phase support will improve ongoing pregnancy rate in women with normal ovarian reserve in fresh embryo transfer cycles.
Infertility is a growing reproductive health problem, and it is estimated that approximately 15% of couples of reproductive ages are affected. The invention and popularity of IVF-ET technology, although improving sperm egg encounter and fertilization barriers and implanting early embryos from the uterine cavity in vitro, still do not solve the problem of the uterine implantation environment or endometrial receptivity, and the pregnancy rate needs to be further improved. However, traditional Chinese medicine (TCM) has an original theoretical understanding and exact efficacy for gynecological diseases, therefore, it is necessary to supplement TCM interventions with endometrial receptivity as described above.
TCM is a kind of traditional treatment method with thousands of years history in China, and some previous studies have shown its unique experience in assisting pregnancy and reduce vaginal bleeding in early pregnancy . Similar to the notion of "hypothalamus- pituitary-ovary axis" that is established by Western medicine, TCM also has deeply studied the reproductive regulation of kidney and proposed the concept of "kidney-Tian Gui-Chong Ren-uterine axis." According to TCM, "Kidney Governs Reproduction," and female infertility is closely related to kidney deficiency, and the main therapeutic principle of it involves tonification of the kidney.
GSATP is widely used as an adjunctive therapy in women with threatened abortion in China and the clinical effects reflected by the patients remained satisfactory. The function of GSATP is nourishing yin and tonifying the kidney, strengthening Chong and prevent miscarriage. GSATP is used in the early threatened abortion, which belongs to the kidney yin deficiency syndrome of traditional Chinese medicine. GSATP is made up of Dodder, uncaria, Scutellaria, Atractylodes macrocephala, white peony, rehmannia, Polygonum multiflorum, Dipsacus, Cistanche deserticola, mulberry parasitism. The main components of GSATP include baicalin, Atractylodes macrocephala polysaccharide, flavonoids from Cuscuta chinensis, rhynchophylline, polysaccharides, Cistanche polysaccharides, stilbene glycosides and anthraquinone glycosides and triterpenoid saponins, etc. Modern pharmacological studies have found that these ingredients can improve vascular function, regulate immune activity, inhibit uterine contraction and improve ovarian endocrine function, so GSATP may play a role in promoting embryo implantation and preventing pregnancy. However, to improve the success rate of embryo implantation is a complex process and has not been fully studied. Therefore, in treating complex diseases, multi-targeted therapy such as TCM might have unique advantages over western medicine treatment alone. Although GSATP is associated with very good response in patients, lack of high-quality evidence-based medicine has restricted its promotion. The combination of evidence-based medicine, modern medicine and traditional Chinese medicine is a huge field that involves continuous attention and efforts.
GSATP dramatically increased the ongoing pregnancy rate and decreased the prevalence of vaginal bleeding in patients undergoing frozen thawed embryo transfer in our previous study. Recently, it was demonstrated that luteal support combined with GSATP could dramatically increase embryo implantation and clinical pregnancy rates, as well as early pregnancy loss rates, in IVF-ET fresh embryo transfer cycles. However, the study's methodological deficiencies prevented it from reaching a definitive conclusion about GSATP's treatment effect. This was mostly attributed to the unspecified randomization process, the absence of distribution concealment and blinding, no placebo control, and vague inclusion and exclusion criteria. As a result, a well-designed randomized clinical trial is essential to estimate the efficiency and safety of GSATP in optimizing reproductive outcomes in women with normal ovarian reserve during fresh embryo transfer cycles.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Gushen Antai Pill (GSATP, 6g\* 9 bags, Beijing boran Pharmaceutical Inc.) was required to be taken orally, 6g three times daily combined with vaginal progesterone (90 mg/day Crinone, Merck) from the day of embryo transfer until 10th gestational week.
Drug: Gushen Antai Pill
Placebo pill is made up of a certain amount of starch and glucose, and is shaped like GSATP according to the National Drug Standards of the State Food and Drug Administration of China. Placebo pill was required to be taken orally, 6g three times daily combined with vaginal progesterone (90 mg/day Crinone, Merck) from the day of embryo transfer until 10th gestational week.
Drug: Placebo pill
The Gushen Antai Pill (GSATP, Z20030144) is composed of 10 herbs including radix-polygoni multiflori, radix rehmanniae praeparata, cistanche salsa, radix dipsaci, uncaria, semen cuscutae, rhizoma atractylodis macrocephalae, radix scutellariae, radix paeoniae lactiflorae. Its production follows GMP standards and takes the form of water honey pills, each bag of 6g.
The placebo pill is produced by Beijing boran Pharmaceutical Co., Ltd. It can simulate the appearance, color and smell of GSATP formula, but it has no clinical effect because it has no active ingredients.
Ongoing pregnancy rate
A fetal heartbeat detected by transvaginal ultrasonography over 12 gestational weeks. \[Detected via ultrasound\]
Time frame: 10 weeks after the day of embryo transfer
Positive pregnancy rate
Serum β-hCG level ≥ 10mIU/mL, 14 days after embryo transfer. \[Detected via ELISA\]
Time frame: 2 weeks after the day of embryo transfer
Embryo implantation rate
The number of intrauterine gestational sacs observed divided by the number of embryos transferred. \[Detected via ultrasound\]
Time frame: 3 weeks after the day of embryo transfer
Clinical pregnancy rate
An intrauterine gestational sac with fetal heartbeat detected by transvaginal ultrasonography. \[Detected via ultrasound\]
Time frame: 4 weeks after the day of embryo transfer
Ectopic pregnancy rate
A pregnancy in which implantation takes place outside the uterine cavity. \[Detected via ultrasound\]
Time frame: 4 weeks after the day of embryo transfer
Pregnancy loss rate
Clinically recognized spontaneous loss of pregnancy before the completion of twelve gestational weeks. \[Detected via ultrasound\]
Time frame: 10 weeks after the day of embryo transfer
Multiple pregnancy rate
There were two or more simultaneous fetuses in the uterine cavity. \[Detected via ultrasound\]
Time frame: 10 weeks after the day of embryo transfer
The prevalence of pregnancy constipation
Functional constipation as the presence of at least two out of six symptoms: straining, lumpy or hard stools, a sensation of incomplete evacuation, a sensation of anorectal obstruction/blockage, manual manoeuvres to facilitate defecation and fewer than three spontaneous bowel movements per week. Symptoms must be present at 25% of the defecations and last at least one months. \[Evaluated via questionnaire\]
Time frame: 10 weeks after the day of embryo transfer
The prevalence of threatened abortion
Abdominal pain and vaginal bleeding happened in the first trimester, but the intrauterine fetus still survived. \[Detected via ultrasound\]
Time frame: 10 weeks after the day of embryo transfer
Live birth rate
Live birth, defined as the birth of at least one child with breath and heartbeat.
Time frame: Beyond 24 weeks of gestation
Plan to share: No
Started Jun 2021 (actual). Primary completion is estimated for Jun 2026, 60 months after the start.
Of 32 non-industry phase 4 interventional studies under Infertility, Female, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's planned 60 months is above that.
Counting every sponsor, half of 37 studies reached it within 20 months; a quarter within 14 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shandong University of Traditional Chinese Medicine